Table 2.
Prevalence of comorbidities in patients with head and neck squamous cell carcinoma in the training set.
| Comorbidity | Patients, n (%) |
|---|---|
| Synchronous SPM | 92 (13.2) |
| Gastric cancer | 19 (2.7) |
| Head and neck cancer | 9 (1.3) |
| Lung cancer | 6 (0.8) |
| Oesophageal cancer | 48 (6.9) |
| Other | 21 (3.0) |
| Metachronous SPM | 110 (15.8) |
| Gastric cancer | 19 (2.7) |
| Head and neck cancer | 33 (4.7) |
| Lung cancer | 8 (1.1) |
| Oesophageal cancer | 32 (4.6) |
| Other | 30 (4.3) |
| Diabetes | 98 (14.0) |
| Peptic ulcer disease | 44 (6.3) |
| Cerebrovascular disease | 41 (5.9) |
| Chronic pulmonary disease | 40 (5.7) |
| Peripheral vascular disease | 20 (2.9) |
| Liver disease | 33 (4.7) |
| Mild | 21 (3.0) |
| Moderate/severe | 12 (1.7) |
| Cardiac arrhythmia | 18 (2.6) |
| Renal disease | 16 (2.3) |
| Myocardial infarction | 10 (1.4) |
| Connective tissue disease | 8 (1.1) |
| Psychiatric disorders | 7 (1.0) |
| Congestive heart failure | 5 (0.7) |
| Dementia | 4 (0.6) |
SPM, secondary primary malignancy.